Correction

Correction: Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance

Dzhamal T Abdurakhmanov1*, Teona P Rozina1,2, Elena N Nikulkina1, Ekaterina A Nabatchikova1, Vladimir P Chulanov1,3, Sergey V Moiseev1,2

1Sechenov First Moscow State Medical University, Moscow, Russia
2Lomonosov Moscow State University, Moscow, Russia
3Central Research Institute of Epidemiology, Moscow, Russia

*Corresponding author e-mail: abdjamal@mail.ru

The publisher would like to report an error that appeared in a recently published article [1]. The word ‘dasabuvir’ should have read ‘daclatasvir’ in the paragraph regarding Patient 3. The correct sentence is as follows: ‘The patient was treated twice with sofosbuvir and daclatasvir for 12 weeks and then with RBV for 24 weeks’. This has been corrected as of 10 October 2018. The authors apologize for this error.

Accepted 10 October 2018; published online 10 October 2018

References